

Preclinical Development of a High-Performance Iron-Based MRI Contrast Agent Specialized for MR Cholangiopancreatography toward Phase 1/2a IND



GASTROINTESTINAL	Preclinical
Product Type	Others-Synth.
Indication	Magnetic resonance cholangiopancreatography (MRCP)
Target	Pancreatobiliary diseases including cholangiocarcinoma, pancreatic cancer, gallbladder cancer, cholangitis, pancreatitis, cholecystitis, and gallstones
MoA(Mechanism of Action)	INV-003 suppresses T ₂ signals from the stomach and duodenum.
Competitiveness	<ul style="list-style-type: none"> • Pancreatobiliary diseases are known for their poor prognosis and high cancer-related mortality rates, making early diagnosis critically important. There are currently no orally administered MRI contrast agents available for this purpose. • INV-003 is world's first MRCP-specific contrast agent, enabling high-resolution and precise imaging of the biliary and pancreatic ducts, thereby improving diagnostic accuracy of pancreatobiliary diseases.
Development Stage	Preclinical
Route of Administration	Oral administration

Any unauthorized distribution or reproduction of this material is strictly prohibited.